Welcome to our dedicated page for Atossa Therapeutics SEC filings (Ticker: ATOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Atossa Therapeutics, Inc. (Nasdaq: ATOS) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on Atossa’s clinical-stage biopharmaceutical operations, centered on the development of its investigational therapy (Z)-Endoxifen for oncology and other serious conditions.
Through forms such as Form 8-K, investors can review Atossa’s reports of material events, including quarterly financial result announcements, changes in executive leadership, regulatory strategy updates, and notices related to Nasdaq listing compliance. Recent 8-K filings describe financial results for specific quarters, the appointment of a new Chief Financial Officer, the release of an updated corporate presentation, and a notice from Nasdaq regarding the minimum bid price requirement and an extension of the compliance deadline.
Filings also document key regulatory and strategic steps, such as press releases incorporated by reference that outline Atossa’s plans for (Z)-Endoxifen in metastatic breast cancer, neoadjuvant ER+/HER2- disease, breast cancer risk reduction, and Rare Pediatric Disease designation for Duchenne Muscular Dystrophy. Additional materials may discuss intellectual property developments, including patents covering enteric oral formulations and methods of using (Z)-Endoxifen.
Stock Titan enhances these SEC filings with AI-powered summaries that aim to clarify the main points of lengthy documents, helping readers quickly identify items related to clinical programs, regulatory milestones, capital markets matters, and corporate governance. Users can also track insider and executive-related disclosures when reported in current reports or other SEC forms.
By reviewing Atossa’s SEC filings alongside AI-generated insights, investors and researchers can better understand the company’s risk factors, development priorities, financial condition, and the formal regulatory record supporting its (Z)-Endoxifen programs.
QUAY STEVEN C reported acquisition or exercise transactions in this Form 4 filing.
ATOSSA THERAPEUTICS, INC. President & CEO Steven C. Quay received an equity grant of 65,000 restricted stock units of Common Stock. These RSUs vest in three equal annual installments on the first three anniversaries of March 26, 2026. Following the grant, he directly holds 88,038 shares of Common Stock and has indirect ownership of 1,483 shares through Ensisheim Partners, LLC, an entity he wholly owns with Dr. Shu-Chih Chen. The share counts have been adjusted to reflect a one-for-fifteen reverse stock split of Common Stock that occurred on February 2, 2026.
Daniel Mark James reported acquisition or exercise transactions in this Form 4 filing.
Atossa Therapeutics’ Chief Financial Officer Daniel Mark James received a grant of 63,000 restricted stock units of common stock. The award was granted at no cash cost to him and brings his reported direct holdings to 63,000 shares-equivalent.
The RSUs vest in three equal annual installments on the first three anniversaries of March 26, 2026, meaning the award is structured to retain and incentivize the CFO over multiple years.
Atossa Therapeutics, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 7, 2026. Proposals include electing three Class II directors, ratifying Ernst & Young LLP as auditor for 2026, an advisory vote on executive pay, and a possible meeting adjournment to gather more proxies.
The Board is also seeking advance approval to implement, at its discretion within one year, a reverse stock split of the common stock at a ratio between 2:1 and 20:1, solely if needed to maintain compliance with Nasdaq’s minimum bid price rules. The company previously effected a 15:1 reverse split effective February 2, 2026. Common shares outstanding were 8,611,361 as of the March 19, 2026 record date, each entitled to one vote.
Atossa Therapeutics files its annual report as a clinical‑stage biotech focused on breast cancer and related conditions, led by its oral (Z)-endoxifen program in multiple Phase 2 trials and exploratory rare-disease indications including Duchenne muscular dystrophy (DMD) and McCune‑Albright Syndrome.
The company reports research and development expenses of approximately $21.2 million for 2025, up from $14.1 million in 2024, and cash and cash equivalents of about $41.3 million as of December 31, 2025. Management states there is substantial doubt about its ability to continue as a going concern without additional capital, and it does not expect revenue until its drug candidates are approved and commercialized.
To strengthen its financial position and maintain listing, Atossa effected a 1‑for‑15 reverse stock split in February 2026 to regain compliance with Nasdaq’s minimum bid requirement and established a new at‑the‑market facility allowing sales of up to $50,000,000 of common stock. During 2025 all outstanding warrants expired, simplifying the capital structure.
Atossa Therapeutics reported a larger net loss of $34.8M for the year ended December 31, 2025, compared with $25.5M a year earlier, as it increased investment in its lead drug candidate, (Z)-endoxifen.
Total operating expenses rose to $37.1M from $27.6M. Research and development spending climbed 50% to $21.2M, driven mainly by an extra $6.1M on clinical and non-clinical trials and higher regulatory consulting tied to (Z)-endoxifen. General and administrative costs increased 18% to $16.0M, reflecting higher legal expenses related to litigation and patent defense and modestly higher compensation.
The company ended 2025 with cash and cash equivalents of $41.3M, down from $71.1M as it funded operations, while interest income fell to $2.4M from $4.1M due to lower average invested balances. During the year, Atossa secured FDA Rare Pediatric Disease and Orphan Drug designations for (Z)-endoxifen in Duchenne Muscular Dystrophy and strengthened its clinical leadership team to support both breast cancer and rare disease programs.
Atossa Therapeutics, Inc. is soliciting proxies for its 2026 virtual Annual Meeting of Stockholders to be held May 7, 2026, where holders of common stock of record on March 19, 2026 will vote on director elections and several governance matters. The Record Date shows 8,611,361 shares outstanding.
Key items include: (1) election of three Class II directors; (2) ratification of Ernst & Young LLP as auditor; (3) approval of a Certificate of Incorporation amendment authorizing a board-discretion reverse stock split at a ratio of 2:1 to 20:1 to be implemented within one year if the Board deems necessary to maintain Nasdaq listing; (4) advisory approval of executive compensation; and (5) adjournment authority to solicit additional proxies. The Board recommends a vote FOR each proposal. The Proxy Statement notes a prior reverse split at a 15:1 ratio effective February 2, 2026, and states per-share figures are presented on a post-split basis.
Atossa Therapeutics, Inc. entered into a new at-the-market equity offering agreement with Rodman & Renshaw LLC, allowing the company to sell up to $50,000,000 of its common stock from time to time. Shares will be issued under an existing Form S-3 shelf registration and a related prospectus supplement.
Rodman & Renshaw will act as sales agent or principal and earn a commission of up to 3.0% of gross proceeds, plus reimbursed expenses. Atossa plans to use any proceeds mainly for clinical development of its product candidates, as well as working capital and general corporate purposes, with potential future business or asset acquisitions.
The company also terminated its prior Open Market Sale agreement with Jefferies LLC, effective February 19, 2026, incurring no termination penalties and having sold no shares under that earlier arrangement.
Atossa Therapeutics, Inc. has filed a prospectus supplement to sell up to $50,000,000 of its common stock through an at-the-market offering with Rodman & Renshaw LLC under a Sales Agreement. Sales may occur from time to time on Nasdaq or by other permitted methods and Rodman will receive up to a 3.0% commission on gross sales.
The prospectus notes 8,611,428 shares outstanding as of September 30, 2025 and states that all share and per-share amounts in the supplement reflect a 15:1 reverse stock split effective February 2, 2026. Proceeds, if any, are intended for clinical development, working capital and general corporate purposes; actual proceeds depend on the timing and market prices of sales.
Atos Therapeutics, Inc. amended its ATM facility. The prospectus supplement states the company reduced the Maximum Offering Price under its Open Market Sale with Jefferies LLC from $100,000,000 to $0, effective as of February 20, 2026.
No shares have been sold under the ATM Facility as of the date of the supplement.